Gastroenterology -Therapeutics & Hepatology

Therapeutics for Biliary Diseases

Biliary diseases, including cholangitis, cholangiocarcinoma, and primary biliary cholangitis (PBC), present complex challenges requiring advanced therapeutic strategies. Recent innovations in biliary disease management offer promising new options. For primary biliary cholangitis, novel drugs such as obeticholic acid are providing new avenues for treatment, targeting bile acid metabolism to reduce liver inflammation and fibrosis. Endoscopic techniques have also advanced, with improved methods for managing bile duct obstructions and stones. Endoscopic retrograde cholangiopancreatography (ERCP) remains a key tool, but innovations in stenting and balloon dilation techniques are enhancing effectiveness and safety. In biliary cancer management, targeted therapies and immunotherapies are emerging as vital components of treatment. Drugs like ivosidenib and durvalumab are showing promise in improving patient outcomes and survival rates. Furthermore, research into molecular and genetic profiling is paving the way for personalized treatment approaches, offering tailored therapies based on individual disease characteristics. These advancements are refining biliary disease management, improving patient care and outcomes.